Open AccessOne day wonder: Fast resolution of macular edema following intravitreal ranibizumab in retinal venous occlusions
Author(s) -
Lalit Verma,
Arindam Chakravarti,
Avantika Gupta,
Smriti Prakash
Publication year - 2013
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/0301-4738.119458
Subject(s) - medicine , ranibizumab , macular edema , ophthalmology , retinal vein , retinal , branch retinal vein occlusion , central retinal vein occlusion , macular degeneration , edema , visual acuity , optical coherence tomography , bevacizumab , surgery , chemotherapy
Macular edema is a significant cause of vision loss in patients with central retinal vein occlusions and branch retinal vein occlusions. Vascular endothelial growth factor (VEGF) appears to be a key factor in the pathogenesis of this disease. Anti-VEGF therapy, such as intravitreal ranibizumab provides an effective treatment against vision-threatening macular edema. We report three patients of retinal vein occlusion with macular edema who demonstrated overnight resolution of macular edema following treatment with intravitreal ranibizumab (0.5 mg). 3D optical coherence tomography (Optovue) was used as a tool for comparison of the macular thickness before and after treatment. The significant reductions in the central foveal thickness demonstrated in these patients one night after intravitreal injections could have significant influence on modifying current treatment protocols. Early treatment of macular edema related to retinal venous occlusive disease with anti-VEGF injections could result in faster visual rehabilitation in these patients.